Zacks Investment Research upgraded shares of Dermira (NASDAQ:DERM) from a hold rating to a buy rating in a research report sent to investors on Thursday morning. The brokerage currently has $8.25 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
Other research analysts have also issued reports about the stock. BidaskClub lowered shares of Dermira from a strong-buy rating to a buy rating in a research note on Saturday, December 15th. Mizuho reaffirmed a hold rating and issued a $10.00 price target on shares of Dermira in a research note on Tuesday, October 2nd. Cantor Fitzgerald set a $20.00 price target on shares of Dermira and gave the company a buy rating in a research note on Friday, December 28th. ValuEngine raised shares of Dermira from a sell rating to a hold rating in a research note on Thursday, November 1st. Finally, Guggenheim reaffirmed a buy rating and issued a $20.00 price target on shares of Dermira in a research note on Tuesday, November 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $21.04.
Dermira (NASDAQ:DERM) last posted its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.63) by $0.05. The business had revenue of $0.72 million for the quarter, compared to analyst estimates of $0.80 million. Dermira had a negative net margin of 496.49% and a negative return on equity of 184.43%. On average, analysts anticipate that Dermira will post -5.2 earnings per share for the current fiscal year.
In other news, Director Matthew K. Fust sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, October 19th. The shares were sold at an average price of $13.75, for a total transaction of $55,000.00. Following the completion of the sale, the director now owns 14,051 shares in the company, valued at approximately $193,201.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 14.80% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of DERM. Marshall Wace North America L.P. acquired a new stake in Dermira in the 3rd quarter valued at approximately $128,000. grace capital acquired a new position in shares of Dermira in the second quarter worth $153,000. AQR Capital Management LLC acquired a new position in shares of Dermira in the third quarter worth $211,000. First Republic Investment Management Inc. acquired a new position in shares of Dermira in the second quarter worth $221,000. Finally, MetLife Investment Advisors LLC grew its stake in shares of Dermira by 55.6% in the third quarter. MetLife Investment Advisors LLC now owns 28,224 shares of the biopharmaceutical company’s stock worth $308,000 after acquiring an additional 10,085 shares in the last quarter. Hedge funds and other institutional investors own 84.90% of the company’s stock.
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Featured Article: Cost of Capital
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.